These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10666660)

  • 1. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arrhythmias in the intensive care patient.
    Trappe HJ; Brandts B; Weismueller P
    Curr Opin Crit Care; 2003 Oct; 9(5):345-55. PubMed ID: 14508146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral class III antiarrhythmics: what is new?
    Khan MH
    Curr Opin Cardiol; 2004 Jan; 19(1):47-51. PubMed ID: 14688634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer antiarrhythmic drugs.
    Gupta AK; Maheshwari A; Thakur RK; Lokhandwala YY
    Indian Heart J; 2001; 53(3):354-60. PubMed ID: 11516042
    [No Abstract]   [Full Text] [Related]  

  • 7. A benefit-risk assessment of class III antiarrhythmic agents.
    Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C
    Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New antiarrhythmic drugs for the treatment of atrial fibrillation.
    Castro A; Bianconi L; Santini M
    Pacing Clin Electrophysiol; 2002 Feb; 25(2):249-59. PubMed ID: 11916001
    [No Abstract]   [Full Text] [Related]  

  • 10. Azimilide dihydrochloride: a unique class III antiarrhythmic agent.
    Tran HT
    Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pure class III agents for prevention of sudden cardiac death.
    Pratt CM
    J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S82-6. PubMed ID: 12950526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in cardiovascular drug therapy: treatment of atrial arrhythmias with new class III drugs and beyond.
    Pürerfellner H
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Jan; 2(1):79-91. PubMed ID: 15320809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical differences between the newer antiarrhythmic agents.
    Camm AJ
    Europace; 2000 Jul; 1 Suppl C():C16-22. PubMed ID: 11220520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azimilide dihydrochloride, a novel antiarrhythmic agent.
    Karam R; Marcello S; Brooks RR; Corey AE; Moore A
    Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
    Vos MA; Golitsyn SR; Stangl K; Ruda MY; Van Wijk LV; Harry JD; Perry KT; Touboul P; Steinbeck G; Wellens HJ
    Heart; 1998 Jun; 79(6):568-75. PubMed ID: 10078083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
    Nattel S; Liu L; St-Georges D
    Cardiovasc Res; 1998 Mar; 37(3):627-35. PubMed ID: 9659446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
    Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic drugs: present and future.
    Sharma S
    J Assoc Physicians India; 2007 Apr; 55 Suppl():43-6. PubMed ID: 18368867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.
    Singh S
    J Interv Card Electrophysiol; 2004; 10 Suppl 1():71-6. PubMed ID: 14739742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.